Articles about 'AstraZeneca'

Apollo's mission to drive therapeutic innovation

20 June 2017

̽��ֱ��stirrings of a revolution are starting to ripple through hundreds of laboratories. It’s a revolution that aims to result in new medicines – faster and with fewer failures – and it’s being led by three UK universities and three global pharmaceutical companies.

Take your medicine: how research into supply chains will help you take care of yourself

14 June 2017

Researchers are working with pharmaceutical companies to make improvements across the whole supply chain, from how a pill is made to the moment it is swallowed by the patient.

Cambridge joins consortium to launch £40 million Apollo Therapeutics Fund

25 January 2016

Three global pharmaceutical companies and the technology transfer offices of three world-leading universities – Imperial College London, ̽��ֱ�� College London and the ̽��ֱ�� of Cambridge – have joined forces with a combined £40 million to create the Apollo Therapeutics Fund.

Structure of the MMP8 protein. Based on PyMOL rendering of PDB 1a85

Moonlighting molecules: finding new uses for old enzymes

26 November 2015

A collaboration between the ̽��ֱ�� of Cambridge and MedImmune, the global biologics research and development arm of AstraZeneca, has led researchers to identify a potentially significant new application for a well-known human enzyme, which may have implications for treating respiratory diseases such as asthma.

Cambridge researchers and pharma in innovative new consortium to develop and study early stage drugs

28 July 2015

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.

Astrazeneca and Cambridge announce new joint PhD and clinical research scholarships

30 June 2015

AstraZeneca and the ̽��ֱ�� of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research. Two of the schemes are co-funded by the NIHR Cambridge Biomedical Research Centre, a partnership between Cambridge ̽��ֱ�� Hospitals and ̽��ֱ�� of Cambridge.

First of new generation of cancer drugs granted European approval

18 December 2014

A new drug for ovarian cancer, developed by researchers at the ̽��ֱ�� of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. ̽��ֱ��drug, Lynparza, has been granted Marketing Authorisation from the European Commission.

Slideshow: Latest addition to Cambridge Biomedical Campus

18 July 2014

New designs revealed as a public consultation is launched.

̽��ֱ��